Journal Article

Dapagliflozin in Patients with Chronic Kidney Disease

Hou, Fan-Fan, Correa-Rotter, Ricardo, Stefánsson, Bergur V, Langkilde, Anna-Maria, Greene, Tom, Chertow, Glenn M, McMurray, John J.V, Lindberg, Magnus, Sjöström, C. David, Heerspink, Hiddo J.L, Toto, Roberto D, Wheeler, David C, Mann, Johannes F.E, Rossing, Peter

2020

Overview

In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes — was less frequent with dapagliflozin.

• Publisher: Massachusetts Medical Society
• Subject: Aged / Albumin / Antidiabetics / Benzhydryl Compounds - adverse effects / Benzhydryl Compounds - pharmacology / Benzhydryl Compounds - therapeutic use / Cardiovascular Diseases - etiology / Cardiovascular Diseases - mortality / Cardiovascular Diseases - prevention & control / Clinical trials / Congestive heart failure / Creatinine / Death / Diabetes / Diabetes mellitus (non-insulin dependent) / Diabetes Mellitus, Type 2 - complications / Diabetes Mellitus, Type 2 - drug therapy / Diabetic Nephropathies - drug therapy / End-stage renal disease / Female / Glomerular filtration rate / Glomerular Filtration Rate - drug effects / Glucose / Glucosides - adverse effects / Glucosides - pharmacology / Glucosides - therapeutic use / Humans / Kaplan-Meier Estimate / Kidney diseases / Kidney Failure, Chronic - mortality / Laboratories / Male / Middle Aged / Population / Regression Analysis / Renal Insufficiency, Chronic - complications / Renal Insufficiency, Chronic - drug therapy / Sodium-Glucose Transporter 2 Inhibitors - adverse effects / Sodium-Glucose Transporter 2 Inhibitors - pharmacology / Sodium-Glucose Transporter 2 Inhibitors - therapeutic use / Statistical analysis